Cassava Sciences Inc

NASDAQ:SAVA   11:19:50 AM EDT
48.45
+0.64 (+1.34%)
Earnings Announcements

Cassava Sciences Announces Full-Year 2020 Financial Results

Published: 03/23/2021 13:41 GMT
Cassava Sciences Inc (SAVA) - Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights.
Cassava Sciences Inc - Believe Cash Levels Support a Pivotal Phase 3 Clinical Program of Simufilam in Alzheimer's Disease.
Cassava Sciences Inc - On-track to Initiate Two Pivotal Phase 3 Studies in Second Half of 2021.
Cassava Sciences Inc - in Mid-year 2021, Also Plans to Initiate a Randomized, Placebo-controlled Cognition Maintenance Study in Alzheimer's Disease.
Cassava Sciences Inc Qtrly Loss per Share 9 Cents.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.16

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.21

More details on our Analysts Page.